Paying People to Take Their Meds

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.

An experimental program in Philadelphia is giving financial incentives to patients who follow their prescriptions for warfarin, a generic anti-blood clotting medication. Patients who don’t properly fill and follow their prescriptions cost the US $100 billion in additional health care costs every year, reports the New York Times. To reduce this waste, the Aetna-sponsored program in Philly creates a lottery-like pool in which patients can win up to $100 a day for taking their prescribed meds.

Two leading causes of prescription non-compliance are cost of medicine and forgetting to take it. In addition, says IMC2, a “brand engagement” company, patients also complain about side-effects and insufficient information. Prescriptions may help certain diseases, but lead to potentially deadly side effects: for example, studies have shown warfarin (prescribed for heart conditions) can significantly raise the risk of death from stroke or internal bleeding. And even without the side-effects, some patients
simply believe they don’t really need the medication. NYT reader Booth Selig, says: “As a 74-year-old, I have fought doctors for years when it comes to various prescribed medicines—multiple heart meds and wafarin being two examples… It is difficult and time consuming to manage, requires weekly doctor visits until regulated, and has caused countless hospitalizations and deaths… Many people no longer trust the FDA or their doctors advice and with good reason.”

If the industry push isn’t enough to increase adherence, encouragement from doctors profiting from their own incentive programs may do the trick. Another Aetna-financed program incorporates bonuses to doctors who prescribe prevention meds, such as beta-blockers to prevent heart attacks.

Despite these programs, there isn’t much proof that incentivizing adherence even works. A US study by Kaiser Permanente showed that after two different incentive programs concluded, the percentage of prescription adherence actually decreased. As the health care industry debates the effectiveness of incentives and the consequences of expanding the Philadelphia program, pharma may come out the winner. Pharmacy marketing consultant Intercontinental Marketing Services (IMS) says: “[t]here is certainly a significant pot of gold at the end of this rainbow. Should we be trying to improve adherence? Yes. Is it complicated and hard to do? Absolutely—but well worth it.”


Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend